12:00 AM
 | 
Oct 21, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/118 cls
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Upgrade Outperform (from neutral) 8% $21.53
Raymond also raised his target to $26 from $25 after FDA extended the PDUFA date by three months for an sNDA for anemia drug Feraheme ferumoxytol. He said applications with three-month PDUFA extensions have a "decent" record of gaining FDA approval. The new date is Jan. 21, 2014. The sNDA seeks to expand Feraheme's indication to all adult patients with iron deficiency anemia who have failed or could not tolerate oral iron treatment. Feraheme is approved to treat iron deficiency anemia in adult patients with chronic kidney disease (CKD).
Amarin Corp. plc(NASDAQ:AMRN) Canaccord Ritu Baral Downgrade Hold (from buy) -60% $2.03
H.C. Wainwright Andrew Fein Downgrade Neutral (from buy)
Baral also lowered her target to $3 from $10 after FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-2 against expanding the label of the company's Vascepa icosapent ethyl...

Read the full 1106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >